Skip to content
OpenCapital
Get started

Halozyme Therapeutics HALO Payment For Induced Conversion of Convertible Debt

Payment For Induced Conversion of Convertible Debt at other companies

Oscar Health logo
Oscar HealthOSCR
$1.11M—
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$4.09M—
AST SpaceMobile logo
AST SpaceMobileASTS
$88.65M—
Oscar Health logo
Oscar HealthOSCR
$3.33M—
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$4.09M—
Bloom Energy logo
Bloom EnergyBE
$16.56M—

Other financials

Income statement

See full
Revenue$376.7M+42.2%
Gross profit$297.5M+37.4%
Operating income$184.5M+30.4%
Net income$150.0M+27.1%
EPS (diluted)$1.22+31.2%

Balance sheet

See full
Cash & equivalents$312.0M+76.9%
Total debt$2.2B+41.7%
Total equity$219.6M-54.5%
Total assets$2.7B+21.7%

Cash flow

See full
Operating cash flow$180.1M+16.8%
CapEx$3.7M+294%
Free cash flow$176.3M+15.0%

Valuation

See full
Market cap$8.13B-2.9%
Enterprise value$10B+3.0%
P/E13.4×-3.8×
P/S5.4×-2.3×

Profitability

See full
Gross margin82.8%-0.7pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin44.3%-1.5pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity9.9×+6.7×
Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept halo:PaymentForInducedConversionOfConvertibleDebt.

The official record: Halozyme Therapeutics’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's payment for induced conversion of convertible debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Halozyme Therapeutics's payment for induced conversion of convertible debt?
Halozyme Therapeutics (HALO) reported payment for induced conversion of convertible debt of $1.37M in Q4 2025.
What does payment for induced conversion of convertible debt mean?
Cash payments made to incentivize holders of convertible debt to convert their holdings into equity earlier than the scheduled maturity date. This is often used to reduce debt obligations and interest expenses on the balance sheet.